Cargando…

Oral Administration of a Shigella 2aT32-Based Vaccine Expressing UreB-HspA Fusion Antigen With and Without Parenteral rUreB-HspA Boost Confers Protection Against Helicobacter pylori in Mice Model

Helicobacter pylori (H. pylori) is a gram-negative pathogen classified as a class I carcinogen. The H. pylori urease B subunit (UreB) and heat shock protein A (HspA) are two important vaccine candidate antigens. In this study, we evaluated the immunogenicity and immunoprotective effect of the attenu...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Xin, Sang, Shuli, Guan, Qing, Tao, Haoxia, Wang, Yanchun, Liu, Chunjie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9234132/
https://www.ncbi.nlm.nih.gov/pubmed/35769459
http://dx.doi.org/10.3389/fimmu.2022.894206
_version_ 1784735988562526208
author Zhang, Xin
Sang, Shuli
Guan, Qing
Tao, Haoxia
Wang, Yanchun
Liu, Chunjie
author_facet Zhang, Xin
Sang, Shuli
Guan, Qing
Tao, Haoxia
Wang, Yanchun
Liu, Chunjie
author_sort Zhang, Xin
collection PubMed
description Helicobacter pylori (H. pylori) is a gram-negative pathogen classified as a class I carcinogen. The H. pylori urease B subunit (UreB) and heat shock protein A (HspA) are two important vaccine candidate antigens. In this study, we evaluated the immunogenicity and immunoprotective effect of the attenuated Shigella vector vaccine SH02 expressing the UreB-HspA fusion protein of H. pylori in a mouse model. Oral SH02 with or without subcutaneous injection of rUreB-HspA induced antigen-specific serum IgG, mucosal sIgA, and T cells immune response. Subcutaneous injection of the candidate antigen rUreB-HspA enhanced the level of serum antigen-specific IgG antibodies (p < 0.0001) and the levels of IgG1/IgG2a/IgG2b subtypes. In addition, injection boost also increased the proportion of spleen antigen-specific CD4+CD154+ T cells (p < 0.001), and the proportion of CD4+CD154+ T cells that secrete IFN-γ and IL-17A. Following the H. pylori challenge, the levels of H. pylori colonization in the two experimental groups (Groups A and B) significantly reduced compared with the control group (p < 0.001), indicating that the candidate vaccine yielded a preventive effect of anti-H.pylori infection. Compared with the non-subcutaneous booster injection group (Group A), the subcutaneous booster injection group (Group B) exhibited less gastric inflammation, but there was no significant difference in the level of colonization (p > 0.05). These results lay a foundation for the development of a vaccine against H. pylori and the optimization of immunization methods and procedures to prevent H. pylori infection.
format Online
Article
Text
id pubmed-9234132
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-92341322022-06-28 Oral Administration of a Shigella 2aT32-Based Vaccine Expressing UreB-HspA Fusion Antigen With and Without Parenteral rUreB-HspA Boost Confers Protection Against Helicobacter pylori in Mice Model Zhang, Xin Sang, Shuli Guan, Qing Tao, Haoxia Wang, Yanchun Liu, Chunjie Front Immunol Immunology Helicobacter pylori (H. pylori) is a gram-negative pathogen classified as a class I carcinogen. The H. pylori urease B subunit (UreB) and heat shock protein A (HspA) are two important vaccine candidate antigens. In this study, we evaluated the immunogenicity and immunoprotective effect of the attenuated Shigella vector vaccine SH02 expressing the UreB-HspA fusion protein of H. pylori in a mouse model. Oral SH02 with or without subcutaneous injection of rUreB-HspA induced antigen-specific serum IgG, mucosal sIgA, and T cells immune response. Subcutaneous injection of the candidate antigen rUreB-HspA enhanced the level of serum antigen-specific IgG antibodies (p < 0.0001) and the levels of IgG1/IgG2a/IgG2b subtypes. In addition, injection boost also increased the proportion of spleen antigen-specific CD4+CD154+ T cells (p < 0.001), and the proportion of CD4+CD154+ T cells that secrete IFN-γ and IL-17A. Following the H. pylori challenge, the levels of H. pylori colonization in the two experimental groups (Groups A and B) significantly reduced compared with the control group (p < 0.001), indicating that the candidate vaccine yielded a preventive effect of anti-H.pylori infection. Compared with the non-subcutaneous booster injection group (Group A), the subcutaneous booster injection group (Group B) exhibited less gastric inflammation, but there was no significant difference in the level of colonization (p > 0.05). These results lay a foundation for the development of a vaccine against H. pylori and the optimization of immunization methods and procedures to prevent H. pylori infection. Frontiers Media S.A. 2022-06-13 /pmc/articles/PMC9234132/ /pubmed/35769459 http://dx.doi.org/10.3389/fimmu.2022.894206 Text en Copyright © 2022 Zhang, Sang, Guan, Tao, Wang and Liu https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Zhang, Xin
Sang, Shuli
Guan, Qing
Tao, Haoxia
Wang, Yanchun
Liu, Chunjie
Oral Administration of a Shigella 2aT32-Based Vaccine Expressing UreB-HspA Fusion Antigen With and Without Parenteral rUreB-HspA Boost Confers Protection Against Helicobacter pylori in Mice Model
title Oral Administration of a Shigella 2aT32-Based Vaccine Expressing UreB-HspA Fusion Antigen With and Without Parenteral rUreB-HspA Boost Confers Protection Against Helicobacter pylori in Mice Model
title_full Oral Administration of a Shigella 2aT32-Based Vaccine Expressing UreB-HspA Fusion Antigen With and Without Parenteral rUreB-HspA Boost Confers Protection Against Helicobacter pylori in Mice Model
title_fullStr Oral Administration of a Shigella 2aT32-Based Vaccine Expressing UreB-HspA Fusion Antigen With and Without Parenteral rUreB-HspA Boost Confers Protection Against Helicobacter pylori in Mice Model
title_full_unstemmed Oral Administration of a Shigella 2aT32-Based Vaccine Expressing UreB-HspA Fusion Antigen With and Without Parenteral rUreB-HspA Boost Confers Protection Against Helicobacter pylori in Mice Model
title_short Oral Administration of a Shigella 2aT32-Based Vaccine Expressing UreB-HspA Fusion Antigen With and Without Parenteral rUreB-HspA Boost Confers Protection Against Helicobacter pylori in Mice Model
title_sort oral administration of a shigella 2at32-based vaccine expressing ureb-hspa fusion antigen with and without parenteral rureb-hspa boost confers protection against helicobacter pylori in mice model
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9234132/
https://www.ncbi.nlm.nih.gov/pubmed/35769459
http://dx.doi.org/10.3389/fimmu.2022.894206
work_keys_str_mv AT zhangxin oraladministrationofashigella2at32basedvaccineexpressingurebhspafusionantigenwithandwithoutparenteralrurebhspaboostconfersprotectionagainsthelicobacterpyloriinmicemodel
AT sangshuli oraladministrationofashigella2at32basedvaccineexpressingurebhspafusionantigenwithandwithoutparenteralrurebhspaboostconfersprotectionagainsthelicobacterpyloriinmicemodel
AT guanqing oraladministrationofashigella2at32basedvaccineexpressingurebhspafusionantigenwithandwithoutparenteralrurebhspaboostconfersprotectionagainsthelicobacterpyloriinmicemodel
AT taohaoxia oraladministrationofashigella2at32basedvaccineexpressingurebhspafusionantigenwithandwithoutparenteralrurebhspaboostconfersprotectionagainsthelicobacterpyloriinmicemodel
AT wangyanchun oraladministrationofashigella2at32basedvaccineexpressingurebhspafusionantigenwithandwithoutparenteralrurebhspaboostconfersprotectionagainsthelicobacterpyloriinmicemodel
AT liuchunjie oraladministrationofashigella2at32basedvaccineexpressingurebhspafusionantigenwithandwithoutparenteralrurebhspaboostconfersprotectionagainsthelicobacterpyloriinmicemodel